Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy VCYT Stock  Free VCYT Stock Alerts

Veracyte (VCYT) Financials

Veracyte logo
$32.14 +0.67 (+2.13%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Veracyte

Annual Income Statements for Veracyte

This table shows Veracyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -34 -31 -31 -23 -13 -35 -76 -37 -74 24
Consolidated Net Income / (Loss)		 -34 -31 -31 -23 -13 -35 -76 -37 -74 24
Net Income / (Loss) Continuing Operations		 -34 -31 -31 -23 -13 -35 -76 -37 -74 24
Total Pre-Tax Income 		-34 -32 -31 -23 -13 -35 -82 -36 -77 26
Total Operating Income		 -33 -29 -27 -22 -15 -35 -82 -41 -86 16
Total Gross Profit		 28 40 44 59 84 76 145 176 230 298
Total Revenue		 50 65 72 92 120 117 220 297 361 446
Operating Revenue		 50 65 72 92 120 117 220 297 361 446
Total Cost of Revenue		 21 25 28 33 37 41 74 121 131 148
Operating Cost of Revenue		 21 25 28 33 37 41 74 102 113 136
Total Operating Expenses		 61 68 70 81 99 111 227 236 334 294
Selling, General & Admin Expense		 23 24 23 24 29 37 101 73 86 111
Marketing Expense		 25 28 32 41 54 52 80 98 101 95
Research & Development Expense		 13 15 14 15 15 17 30 41 57 69
Amortization Expense		 0.80 1.07 1.07 1.07 1.40 5.10 16 21 21 15
Impairment Charge		 - - - - - - 0.00 3.32 68 3.37
Total Other Income / (Expense), net		 -0.38 -2.76 -4.94 -0.77 2.53 0.48 0.25 4.65 9.18 9.60
Other Income / (Expense), net		 - - - 1.20 2.53 0.48 0.25 4.65 9.18 9.60
Income Tax Expense		 - - - - 0.00 0.00 -6.09 0.13 -2.21 1.61
Basic Earnings per Share		 ($1.30) ($1.09) ($0.91) ($0.62) ($0.27) ($0.66) ($1.11) ($0.51) ($1.02) $0.32
Weighted Average Basic Shares Outstanding		 25.99M 28.83M 33.93M 37.02M 46.14M 53.24M 67.89M 71.55M 72.64M 76.48M
Diluted Earnings per Share		 ($1.30) ($1.09) ($0.91) ($0.62) ($0.27) ($0.66) ($1.11) ($0.51) ($1.02) $0.31
Weighted Average Diluted Shares Outstanding		 25.99M 28.83M 33.93M 37.02M 46.14M 53.24M 67.89M 71.55M 72.64M 78.16M
Weighted Average Basic & Diluted Shares Outstanding		 25.99M 28.83M 33.93M 37.02M 46.14M 53.24M 71.22M 72.15M 75.07M 77.94M

Quarterly Income Statements for Veracyte

This table shows Veracyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -8.72 -3.84 -8.09 -8.40 -30 -28 -1.86 5.73 15 5.11
Consolidated Net Income / (Loss)		 -8.72 -3.84 -8.09 -8.40 -30 -28 -1.86 5.73 15 5.11
Net Income / (Loss) Continuing Operations		 -8.72 -3.84 -8.09 -8.40 -30 -28 -1.86 5.73 15 5.11
Total Pre-Tax Income 		-8.88 -3.44 -8.09 -8.28 -30 -30 -1.91 7.36 17 3.44
Total Operating Income		 -9.68 -5.42 -10 -8.05 -32 -36 -4.66 4.61 12 4.18
Total Gross Profit		 50 34 56 56 58 60 65 78 79 76
Total Revenue		 76 80 82 90 90 98 97 114 116 119
Operating Revenue		 76 80 82 90 90 98 97 114 116 119
Total Cost of Revenue		 26 46 26 35 32 38 31 37 37 43
Operating Cost of Revenue		 26 27 26 30 28 29 31 34 34 37
Total Operating Expenses		 59 59 67 69 94 104 70 76 70 77
Selling, General & Admin Expense		 18 15 21 25 16 24 26 32 26 27
Marketing Expense		 26 24 26 26 24 25 24 24 23 25
Research & Development Expense		 11 11 13 13 13 19 16 16 18 19
Amortization Expense		 5.21 5.26 5.33 5.34 5.34 4.56 3.65 3.79 3.80 3.61
Impairment Charge		 0.00 - 1.41 0.00 35 32 0.43 0.00 0.19 2.75
Total Other Income / (Expense), net		 0.81 1.98 2.41 -0.23 1.97 5.04 2.75 2.76 4.83 -0.73
Other Income / (Expense), net		 0.81 1.98 2.41 -0.23 1.97 5.04 2.75 2.76 4.83 -0.73
Income Tax Expense		 -0.15 0.40 0.00 0.13 -0.15 -2.18 -0.04 1.63 1.69 -1.67
Basic Earnings per Share		 ($0.12) ($0.06) ($0.11) ($0.12) ($0.41) ($0.38) ($0.02) $0.07 $0.20 $0.07
Weighted Average Basic Shares Outstanding		 71.66M 71.55M 72.18M 72.48M 72.80M 72.64M 74.76M 76.54M 77.01M 76.48M
Diluted Earnings per Share		 ($0.12) ($0.06) ($0.11) ($0.12) ($0.41) ($0.38) ($0.02) $0.07 $0.19 $0.07
Weighted Average Diluted Shares Outstanding		 71.66M 71.55M 72.18M 72.48M 72.80M 72.64M 74.76M 77.16M 78.46M 78.16M
Weighted Average Basic & Diluted Shares Outstanding		 71.75M 72.15M 72.75M - 73.04M 75.07M 76.45M 76.81M 77.50M 77.94M

Annual Cash Flow Statements for Veracyte

This table details how cash moves in and out of Veracyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 4.07 20 -25 44 81 190 -176 -19 62 23
Net Cash From Operating Activities		 -27 -28 -24 -14 -3.23 -9.71 -32 7.54 44 75
Net Cash From Continuing Operating Activities		 -27 -28 -24 -14 -3.23 -9.71 -32 7.54 44 75
Net Income / (Loss) Continuing Operations		 -34 -31 -31 -23 -13 -35 -76 -37 -74 24
Consolidated Net Income / (Loss)		 -34 -31 -31 -23 -13 -35 -76 -37 -74 24
Depreciation Expense		 2.25 3.51 3.84 3.92 4.12 7.94 20 26 27 23
Non-Cash Adjustments To Reconcile Net Income		 5.79 7.05 8.22 6.18 11 16 26 34 105 47
Changes in Operating Assets and Liabilities, net		 -1.35 -6.41 -5.44 -0.65 -5.88 1.03 -1.23 -16 -13 -19
Net Cash From Investing Activities		 -6.70 -4.21 -1.32 -1.87 -43 -3.84 -739 -29 15 -56
Net Cash From Continuing Investing Activities		 -6.70 -4.21 -1.32 -1.87 -43 -3.84 -739 -29 15 -56
Purchase of Property, Plant & Equipment		 -6.17 -4.21 -1.76 -1.87 -2.76 -2.84 -5.38 -8.55 -9.96 -11
Acquisitions		 0.00 - 0.00 0.00 -40 0.00 -737 0.00 0.00 5.01
Purchase of Investments		 - - - 0.00 0.00 -1.00 0.00 -34 -20 -50
Sale and/or Maturity of Investments		 - - - - - 0.00 0.00 13 45 0.00
Net Cash From Financing Activities		 38 52 -0.22 59 127 204 596 3.49 2.84 4.90
Net Cash From Continuing Financing Activities		 38 52 -0.22 59 127 204 596 3.49 2.84 4.90
Repayment of Debt		 0.00 -5.00 -26 0.00 -25 -0.10 0.00 -1.28 0.00 0.00
Other Financing Activities, net		 0.48 0.93 0.36 4.46 14 9.86 2.50 4.78 2.84 4.90
Effect of Exchange Rate Changes		 - - - - - 0.00 -1.51 -0.59 0.16 -0.42
Cash Interest Paid		 0.28 2.15 2.72 1.55 0.33 0.01 0.01 0.01 0.00 0.00
Cash Income Taxes Paid		 0.02 0.01 0.02 0.08 0.04 0.11 0.11 0.57 1.70 2.24

Quarterly Cash Flow Statements for Veracyte

This table details how cash moves in and out of Veracyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 17 -16 24 13 11 14 -7.06 27 38 -35
Net Cash From Operating Activities		 7.03 9.74 -2.17 17 14 16 -8.97 30 30 25
Net Cash From Continuing Operating Activities		 7.03 9.74 -2.17 17 14 16 -8.97 30 30 25
Net Income / (Loss) Continuing Operations		 -8.72 -3.84 -8.09 -8.40 -30 -28 -1.86 5.73 15 5.11
Consolidated Net Income / (Loss)		 -8.72 -3.84 -8.09 -8.40 -30 -28 -1.86 5.73 15 5.11
Depreciation Expense		 6.32 6.56 6.67 6.86 7.32 6.34 5.59 5.74 5.88 6.25
Non-Cash Adjustments To Reconcile Net Income		 9.11 6.79 10 12 44 39 10 11 8.66 17
Changes in Operating Assets and Liabilities, net		 0.32 0.24 -11 6.69 -7.67 -1.45 -23 6.80 0.28 -3.52
Net Cash From Investing Activities		 8.81 -26 24 -3.67 -2.80 -2.50 2.88 -2.77 -2.24 -54
Net Cash From Continuing Investing Activities		 8.81 -26 24 -3.67 -2.80 -2.50 2.88 -2.77 -2.24 -54
Purchase of Property, Plant & Equipment		 -1.71 -1.87 -0.99 -3.67 -2.80 -2.50 -2.13 -2.77 -2.24 -4.14
Purchase of Investments		 - -25 -20 - - - 0.00 - - -50
Net Cash From Financing Activities		 1.49 0.09 1.69 0.40 0.11 0.65 -0.86 -0.01 10 -4.51
Net Cash From Continuing Financing Activities		 1.49 0.09 1.69 0.40 0.11 0.65 -0.86 -0.01 10 -4.51
Other Financing Activities, net		 1.48 1.28 1.69 0.40 0.11 0.65 -0.86 -0.01 10 -4.51
Effect of Exchange Rate Changes		 -0.65 0.73 0.05 -0.01 -0.18 0.30 -0.11 -0.06 0.15 -0.40
Cash Income Taxes Paid		 0.37 0.14 - - 1.27 0.43 - - 1.19 1.03

Annual Balance Sheets for Veracyte

This table presents Veracyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 75 101 79 121 275 457 1,188 1,156 1,115 1,300
Total Current Assets		 48 74 54 97 188 376 243 249 286 372
Cash & Equivalents		 39 59 34 78 159 349 173 154 216 239
Short-Term Investments		 - - - - - - 3.96 25 0.00 50
Accounts Receivable		 3.50 8.76 13 13 19 18 41 44 40 47
Inventories, net		 3.77 3.48 5.32 3.40 6.81 4.66 11 14 16 22
Prepaid Expenses		 1.44 2.06 2.00 2.39 2.24 3.20 13 11 13 15
Plant, Property, & Equipment, net		 10 11 9.69 8.94 8.93 8.99 15 18 21 23
Total Noncurrent Assets		 17 16 15 15 79 72 930 890 809 905
Goodwill		 1.06 1.06 1.06 1.06 2.73 2.73 708 696 703 746
Intangible Assets		 15 14 13 12 65 60 203 175 89 102
Other Noncurrent Operating Assets		 0.16 0.13 0.33 1.09 10 9.24 18 19 16 55
Other Noncurrent Nonoperating Assets		 0.60 0.60 0.60 0.60 0.60 0.60 0.75 0.75 0.88 1.54
Total Liabilities & Shareholders' Equity		 75 101 79 121 275 457 1,188 1,156 1,115 1,300
Total Liabilities		 24 41 41 41 36 36 91 81 71 124
Total Current Liabilities		 15 12 12 13 17 17 64 63 61 79
Short-Term Debt		 - - 0.00 1.36 1.41 0.00 3.81 6.06 2.66 17
Accounts Payable		 5.09 2.42 3.85 2.52 2.33 3.12 12 12 13 8.63
Accrued Expenses		 8.69 9.11 8.18 9.19 14 12 39 38 38 44
Current Deferred Revenue		 0.95 - - - 0.00 0.37 4.65 2.61 2.01 1.67
Other Current Liabilities		 - - - 0.00 - 1.59 3.86 4.26 5.21 7.52
Total Noncurrent Liabilities		 9.27 30 29 28 18 19 27 19 9.56 45
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - 0.00 5.59 4.53 0.73 1.23
Other Noncurrent Operating Liabilities		 - - - 0.00 18 18 21 14 8.83 44
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 51 60 37 80 239 421 1,097 1,075 1,044 1,176
Total Preferred & Common Equity		 51 60 37 80 239 421 1,097 1,075 1,044 1,176
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 51 60 37 80 239 421 1,097 1,075 1,044 1,176
Common Stock		 200 240 248 314 486 703 1,469 1,500 1,536 1,656
Retained Earnings		 -149 -180 -211 -234 -247 -282 -357 -394 -468 -444
Accumulated Other Comprehensive Income / (Loss)		 - - - - - 0.00 -15 -31 -24 -36

Quarterly Balance Sheets for Veracyte

This table presents Veracyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 1,126 1,161 1,125 1,200 1,234 1,275
Total Current Assets		 239 259 271 290 321 357
Cash & Equivalents		 170 191 202 209 236 274
Accounts Receivable		 40 42 39 47 50 49
Inventories, net		 14 12 16 18 19 20
Prepaid Expenses		 15 14 14 16 16 14
Plant, Property, & Equipment, net		 17 19 19 22 22 21
Total Noncurrent Assets		 870 883 834 888 891 897
Goodwill		 677 699 693 754 752 762
Intangible Assets		 177 165 124 116 113 109
Other Noncurrent Operating Assets		 16 19 17 17 25 25
Other Noncurrent Nonoperating Assets		 0.75 0.89 0.87 1.08 1.09 1.08
Total Liabilities & Shareholders' Equity		 1,126 1,161 1,125 1,200 1,234 1,275
Total Liabilities		 78 78 71 81 102 99
Total Current Liabilities		 58 58 57 58 72 70
Short-Term Debt		 7.10 3.36 2.57 6.93 7.35 7.39
Accounts Payable		 11 13 13 12 12 9.67
Accrued Expenses		 32 34 35 30 43 44
Current Deferred Revenue		 3.86 2.38 2.21 2.60 2.20 2.03
Other Current Liabilities		 4.14 5.09 5.11 6.07 7.26 7.35
Total Noncurrent Liabilities		 19 20 14 23 29 29
Noncurrent Deferred & Payable Income Tax Liabilities		 4.34 4.71 3.64 1.34 1.48 1.47
Other Noncurrent Operating Liabilities		 15 16 9.98 22 28 27
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,048 1,083 1,054 1,119 1,133 1,176
Total Preferred & Common Equity		 1,048 1,083 1,054 1,119 1,133 1,176
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,048 1,083 1,054 1,119 1,133 1,176
Common Stock		 1,492 1,521 1,528 1,618 1,627 1,646
Retained Earnings		 -390 -410 -440 -470 -464 -449
Accumulated Other Comprehensive Income / (Loss)		 -54 -28 -34 -29 -31 -21

Annual Metrics and Ratios for Veracyte

This table displays calculated financial ratios and metrics derived from Veracyte's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 29.62% 31.48% 10.55% 27.87% 30.82% -2.40% 86.85% 35.09% 21.76% 23.46%
EBITDA Growth		 -12.48% 16.36% 14.74% 23.13% 50.84% -221.05% -130.14% 83.08% -370.75% 199.55%
EBIT Growth		 -15.38% 13.93% 7.86% 20.73% 40.11% -177.08% -133.89% 55.39% -110.32% 133.60%
NOPAT Growth		 -15.38% 13.93% 7.86% 16.22% 31.96% -133.95% -131.44% 49.84% -108.84% 125.20%
Net Income Growth		 -14.74% 6.96% 1.13% 25.82% 45.22% -177.08% -116.46% 51.62% -103.51% 132.44%
EPS Growth		 4.41% 16.15% 16.51% 31.87% 56.45% -144.44% -68.18% 54.05% -100.00% 130.39%
Operating Cash Flow Growth		 2.41% -3.77% 14.53% 43.46% 76.10% -200.46% -225.62% 123.83% 486.89% 69.82%
Free Cash Flow Firm Growth		 30.50% -0.39% 25.91% 16.23% -245.27% 75.42% -5,867.08% 99.12% 252.12% -571.50%
Invested Capital Growth		 48.15% 53.05% 11.21% 8.44% 169.09% -11.71% 1,179.80% -2.25% -8.01% 8.74%
Revenue Q/Q Growth		 3.87% 6.92% 1.90% 7.17% 3.42% 4.27% 17.57% 4.57% 5.22% 4.80%
EBITDA Q/Q Growth		 1.11% 12.26% -4.54% 18.07% -37.91% 4.76% 0.60% 52.75% -122.90% 220.10%
EBIT Q/Q Growth		 0.32% 12.93% -9.82% 16.59% -26.15% 1.70% -5.16% 24.10% -54.52% 415.07%
NOPAT Q/Q Growth		 0.32% 12.93% -9.82% 11.84% -51.47% 0.35% -5.49% 14.40% -54.01% 191.85%
Net Income Q/Q Growth		 0.38% 10.32% -14.97% 18.83% -52.79% -1.71% -3.40% 15.46% -48.94% 360.44%
EPS Q/Q Growth		 5.11% 12.80% -13.75% 23.46% -58.82% 4.35% 0.00% 10.53% -45.71% 321.43%
Operating Cash Flow Q/Q Growth		 17.21% -5.27% -7.09% 25.34% 48.27% 4.63% 16.36% 20.81% 15.12% 13.57%
Free Cash Flow Firm Q/Q Growth		 5.39% 2.61% -2.68% -2.45% -283.20% 77.89% 1.45% -128.57% 254.49% 19.67%
Invested Capital Q/Q Growth		 2.89% 11.93% 5.99% 15.62% 130.62% -9.16% -2.50% 1.95% -2.80% -0.69%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 56.57% 60.88% 60.81% 64.05% 69.66% 64.71% 66.11% 59.24% 63.62% 66.88%
EBITDA Margin		 -62.96% -40.05% -30.89% -18.57% -6.98% -22.95% -28.27% -3.54% -13.69% 11.04%
Operating Margin		 -67.60% -44.25% -36.88% -24.16% -12.57% -30.12% -37.31% -13.85% -23.76% 3.62%
EBIT Margin		 -67.60% -44.25% -36.88% -22.86% -10.47% -29.71% -37.20% -12.28% -21.22% 5.78%
Profit (Net Income) Margin		 -68.08% -48.18% -43.09% -25.00% -10.47% -29.71% -34.42% -12.33% -20.61% 5.42%
Tax Burden Percent		 99.59% 99.36% 98.49% 100.00% 100.00% 100.00% 92.55% 100.37% 97.12% 93.76%
Interest Burden Percent		 101.13% 109.57% 118.62% 109.33% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.24%
Return on Invested Capital (ROIC)		 -170.17% -96.95% -69.92% -53.38% -18.91% -32.23% -11.53% -3.15% -6.94% 1.75%
ROIC Less NNEP Spread (ROIC-NNEP)		 -138.60% -64.61% -13.02% -28.03% -16.97% -28.23% -4.56% 1.34% 0.45% -1.94%
Return on Net Nonoperating Assets (RNNOA)		 97.40% 40.36% 5.87% 14.05% 11.02% 21.66% 1.57% -0.21% -0.08% 0.43%
Return on Equity (ROE)		 -72.77% -56.59% -64.05% -39.32% -7.89% -10.57% -9.96% -3.37% -7.02% 2.17%
Cash Return on Invested Capital (CROIC)		 -208.98% -138.87% -80.54% -61.47% -110.54% -19.79% -182.54% -0.88% 1.41% -6.63%
Operating Return on Assets (OROA)		 -47.78% -32.68% -29.54% -21.11% -6.37% -9.53% -9.93% -3.11% -6.75% 2.13%
Return on Assets (ROA)		 -48.12% -35.58% -34.50% -23.08% -6.37% -9.53% -9.19% -3.12% -6.55% 2.00%
Return on Common Equity (ROCE)		 -72.77% -56.59% -64.05% -39.32% -7.89% -10.57% -9.96% -3.37% -7.02% 2.17%
Return on Equity Simple (ROE_SIMPLE)		 -65.76% -52.63% -83.29% -28.84% -5.26% -8.29% -6.89% -3.40% -7.13% 2.05%
Net Operating Profit after Tax (NOPAT)		 -23 -20 -19 -16 -11 -25 -57 -29 -60 15
NOPAT Margin		 -47.32% -30.98% -25.82% -16.91% -8.80% -21.09% -26.12% -9.70% -16.63% 3.40%
Net Nonoperating Expense Percent (NNEP)		 -31.58% -32.34% -56.91% -25.35% -1.94% -4.00% -6.97% -4.49% -7.39% 3.68%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -2.66% -5.74% 1.27%
Cost of Revenue to Revenue		 43.43% 39.12% 39.19% 35.95% 30.34% 35.29% 33.89% 40.76% 36.38% 33.12%
SG&A Expenses to Revenue		 45.62% 36.55% 32.09% 26.04% 24.12% 31.26% 46.17% 24.69% 23.88% 24.81%
R&D to Revenue		 25.85% 23.54% 19.29% 16.11% 12.34% 14.64% 13.60% 13.69% 15.87% 15.55%
Operating Expenses to Revenue		 124.18% 105.13% 97.70% 88.21% 82.22% 94.84% 103.42% 79.60% 92.49% 65.85%
Earnings before Interest and Taxes (EBIT)		 -33 -29 -27 -21 -13 -35 -82 -36 -77 26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -31 -26 -22 -17 -8.40 -27 -62 -10 -49 49
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.89 3.63 5.97 6.39 5.69 6.73 2.67 1.58 1.92 2.61
Price to Tangible Book Value (P/TBV)		 5.69 4.87 9.62 7.65 7.94 7.90 15.75 8.33 7.96 9.36
Price to Revenue (P/Rev)		 4.02 3.32 3.09 5.54 11.33 24.12 13.33 5.74 5.57 6.88
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 127.14
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.79%
Enterprise Value to Invested Capital (EV/IC)		 10.04 7.26 7.64 15.20 14.78 34.48 2.99 1.70 2.16 3.10
Enterprise Value to Revenue (EV/Rev)		 3.33 2.80 2.97 5.01 10.02 21.15 12.54 5.16 4.97 6.27
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 56.84
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 108.63
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 184.77
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 203.04 40.60 37.24
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 147.49 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.10 0.43 0.68 0.37 0.01 0.00 0.00 0.01 0.00 0.01
Long-Term Debt to Equity		 0.10 0.43 0.68 0.35 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.70 -0.62 -0.45 -0.50 -0.65 -0.77 -0.34 -0.16 -0.18 -0.22
Leverage Ratio		 1.51 1.59 1.86 1.70 1.24 1.11 1.08 1.08 1.07 1.09
Compound Leverage Factor		 1.53 1.74 2.20 1.86 1.24 1.11 1.08 1.08 1.07 1.09
Debt to Total Capital		 8.87% 29.99% 40.41% 26.79% 0.87% 0.19% 0.35% 0.56% 0.25% 1.42%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 1.25% 0.58% 0.00% 0.35% 0.56% 0.25% 1.42%
Long-Term Debt to Total Capital		 8.87% 29.99% 40.41% 25.54% 0.29% 0.19% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.13% 70.01% 59.59% 73.21% 99.13% 99.81% 99.65% 99.44% 99.75% 98.58%
Debt to EBITDA		 -0.16 -0.98 -1.14 -1.71 -0.25 -0.03 -0.06 -0.58 -0.05 0.35
Net Debt to EBITDA		 1.10 1.30 0.39 2.86 18.72 12.93 2.79 16.46 4.33 -5.54
Long-Term Debt to EBITDA		 -0.16 -0.98 -1.14 -1.63 -0.08 -0.03 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.21 -1.27 -1.36 -1.88 -0.20 -0.03 -0.07 -0.21 -0.04 1.12
Net Debt to NOPAT		 1.46 1.68 0.47 3.14 14.85 14.07 3.02 6.01 3.56 -18.00
Long-Term Debt to NOPAT		 -0.21 -1.27 -1.36 -1.79 -0.07 -0.03 0.00 0.00 0.00 0.00
Altman Z-Score		 1.93 1.08 -0.10 5.79 22.66 47.40 18.95 12.45 16.78 15.04
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.25 6.38 4.48 7.42 10.74 22.39 3.79 3.97 4.66 4.73
Quick Ratio		 2.89 5.89 3.87 6.98 10.23 21.92 3.41 3.56 4.19 4.27
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -29 -21 -18 -62 -15 -908 -8.00 12 -57
Operating Cash Flow to CapEx		 -437.39% -664.66% -1,818.63% -721.50% -118.26% -342.30% -588.19% 88.14% 443.95% 665.33%
Free Cash Flow to Firm to Interest Expense		 -76.11 -10.48 -4.33 -9.13 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -71.34 -10.15 -4.84 -6.89 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -87.65 -11.68 -5.11 -7.84 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.71 0.74 0.80 0.92 0.61 0.32 0.27 0.25 0.32 0.37
Accounts Receivable Turnover		 15.11 10.62 6.70 7.11 7.41 6.22 7.33 6.94 8.56 10.26
Inventory Turnover		 5.76 7.03 6.41 7.58 7.16 7.23 9.37 9.47 8.64 7.79
Fixed Asset Turnover		 6.84 5.97 6.80 9.88 13.47 13.11 18.23 18.08 18.86 20.48
Accounts Payable Turnover		 3.44 6.78 8.98 10.39 15.08 15.23 9.61 9.96 10.57 13.68
Days Sales Outstanding (DSO)		 24.16 34.37 54.46 51.34 49.27 58.70 49.82 52.61 42.66 35.58
Days Inventory Outstanding (DIO)		 63.36 51.91 56.95 48.14 51.01 50.46 38.96 38.54 42.26 46.83
Days Payable Outstanding (DPO)		 105.97 53.82 40.63 35.14 24.20 23.97 37.96 36.65 34.53 26.68
Cash Conversion Cycle (CCC)		 -18.45 32.46 70.79 64.35 76.07 85.20 50.81 54.49 50.40 55.73
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 16 25 28 30 82 72 922 902 829 902
Invested Capital Turnover		 3.60 3.13 2.71 3.16 2.15 1.53 0.44 0.33 0.42 0.51
Increase / (Decrease) in Invested Capital		 5.34 8.72 2.82 2.36 51 -9.56 850 -21 -72 73
Enterprise Value (EV)		 165 183 214 461 1,206 2,485 2,754 1,530 1,796 2,797
Market Capitalization		 199 216 222 510 1,364 2,833 2,927 1,703 2,009 3,069
Book Value per Share		 $1.85 $2.13 $1.09 $1.97 $4.90 $7.28 $15.43 $14.98 $14.30 $15.17
Tangible Book Value per Share		 $1.26 $1.59 $0.68 $1.65 $3.52 $6.19 $2.62 $2.85 $3.46 $4.23
Total Capital		 56 85 62 109 242 422 1,100 1,081 1,047 1,193
Total Debt		 4.99 26 25 29 2.10 0.81 3.81 6.06 2.66 17
Total Long-Term Debt		 4.99 26 25 28 0.69 0.81 0.00 0.00 0.00 0.00
Net Debt		 -34 -34 -8.65 -49 -157 -349 -173 -173 -214 -272
Capital Expenditures (CapEx)		 6.17 4.21 1.32 1.87 2.73 2.84 5.38 8.55 9.96 11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.01 2.75 8.01 7.26 12 9.53 5.60 13 11 21
Debt-free Net Working Capital (DFNWC)		 33 62 42 85 172 359 183 192 227 311
Net Working Capital (NWC)		 33 62 42 84 170 359 179 186 224 294
Net Nonoperating Expense (NNE)		 10 11 12 7.44 2.01 10 18 7.80 14 -9.00
Net Nonoperating Obligations (NNO)		 -35 -34 -9.25 -49 -158 -349 -174 -174 -215 -274
Total Depreciation and Amortization (D&A)		 2.30 2.74 4.31 3.95 4.20 7.94 20 26 27 23
Debt-free, Cash-free Net Working Capital to Revenue		 -12.14% 4.23% 11.13% 7.89% 10.23% 8.12% 2.55% 4.46% 2.93% 4.75%
Debt-free Net Working Capital to Revenue		 67.05% 95.40% 58.23% 92.66% 142.58% 305.49% 83.26% 64.78% 62.88% 69.68%
Net Working Capital to Revenue		 67.05% 95.40% 58.23% 91.18% 141.41% 305.49% 81.52% 62.73% 62.15% 65.87%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.30) ($1.09) ($0.91) ($0.62) ($0.27) ($0.66) ($1.11) ($0.51) ($1.02) $0.32
Adjusted Weighted Average Basic Shares Outstanding		 27.85M 33.85M 34.29M 41.11M 49.74M 67.00M 67.89M 71.55M 72.64M 76.48M
Adjusted Diluted Earnings per Share		 ($1.30) ($1.09) ($0.91) ($0.62) ($0.27) ($0.66) ($1.11) ($0.51) ($1.02) $0.31
Adjusted Weighted Average Diluted Shares Outstanding		 27.85M 33.85M 34.29M 41.11M 49.74M 67.00M 67.89M 71.55M 72.64M 78.16M
Adjusted Basic & Diluted Earnings per Share		 ($1.30) ($1.09) ($0.91) ($0.62) ($0.27) ($0.66) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 25.99M 28.83M 33.93M 37.02M 46.14M 53.24M 71.22M 72.15M 75.07M 77.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -20 -19 -16 -11 -25 -57 -26 -12 18
Normalized NOPAT Margin		 -47.32% -30.98% -25.82% -16.91% -8.80% -21.09% -26.12% -8.91% -3.38% 4.10%
Pre Tax Income Margin		 -68.37% -48.49% -43.75% -25.00% -10.47% -29.71% -37.20% -12.28% -21.22% 5.78%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -88.53 -10.45 -5.37 -10.72 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -61.97 -7.31 -3.76 -7.93 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -104.84 -11.97 -5.64 -11.67 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -78.28 -8.84 -4.03 -8.88 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Veracyte

This table displays calculated financial ratios and metrics derived from Veracyte's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 25.21% 19.25% 21.60% 23.96% 19.20% 22.29% 17.50% 26.69% 28.58% 20.81%
EBITDA Growth		 72.69% 152.54% 82.03% 55.06% -780.01% -874.83% 359.11% 1,023.77% 201.23% 140.17%
EBIT Growth		 42.66% 72.10% 44.06% 14.20% -235.46% -785.56% 76.42% 188.93% 156.59% 111.30%
NOPAT Growth		 41.97% 56.05% 31.15% 24.99% -227.88% -555.11% 55.65% 163.66% 148.65% 124.95%
Net Income Growth		 38.26% 63.49% 44.05% 11.85% -239.54% -636.03% 76.96% 168.25% 151.17% 118.07%
EPS Growth		 40.00% 50.00% 45.00% 7.69% -241.67% -533.33% 81.82% 158.33% 146.34% 118.42%
Operating Cash Flow Growth		 604.38% 15.37% 75.52% 4,692.56% 101.69% 59.61% -312.80% 77.40% 111.44% 57.69%
Free Cash Flow Firm Growth		 106.24% 101.97% 108.32% 437.58% -83.77% 179.33% -205.66% -199.82% -596.30% -240.02%
Invested Capital Growth		 -6.51% -2.25% -3.31% 0.00% -3.52% -8.01% 2.38% 0.00% 6.44% 8.74%
Revenue Q/Q Growth		 3.74% 6.22% 2.65% 9.58% -0.24% 8.98% -1.38% 18.16% 1.25% 2.39%
EBITDA Q/Q Growth		 19.14% 222.11% -145.62% 0.21% -1,483.15% -7.51% 115.26% 255.76% 73.49% -57.34%
EBIT Q/Q Growth		 8.00% 61.23% -135.14% -2.30% -259.70% -2.35% 93.74% 485.80% 128.88% -79.56%
NOPAT Q/Q Growth		 9.81% 44.01% -93.69% 23.31% -294.22% -11.87% 86.89% 210.09% 201.27% -42.64%
Net Income Q/Q Growth		 8.49% 55.93% -110.48% -3.84% -252.51% 4.47% 93.41% 407.62% 164.30% -66.26%
EPS Q/Q Growth		 7.69% 50.00% -83.33% -9.09% -241.67% 7.32% 94.74% 450.00% 171.43% -63.16%
Operating Cash Flow Q/Q Growth		 2,035.54% 38.68% -122.29% 867.54% -15.00% 9.75% -157.65% 429.86% 1.31% -18.15%
Free Cash Flow Firm Q/Q Growth		 120.55% -69.07% 36.87% 3,780.95% -99.01% 432.38% -151.77% -3,566.61% 95.09% -50.20%
Invested Capital Q/Q Growth		 -2.44% 1.95% -0.84% -100.00% 0.00% -2.80% 10.35% -1.36% 0.60% -0.69%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 65.59% 42.58% 68.18% 61.80% 64.02% 61.08% 67.51% 68.09% 68.19% 63.93%
EBITDA Margin		 -3.37% 3.88% -1.72% -1.57% -24.91% -24.58% 3.80% 11.45% 19.62% 8.17%
Operating Margin		 -12.81% -6.75% -12.74% -8.91% -35.22% -36.16% -4.81% 4.03% 10.37% 3.52%
EBIT Margin		 -11.74% -4.29% -9.82% -9.16% -33.04% -31.03% -1.97% 6.43% 14.54% 2.90%
Profit (Net Income) Margin		 -11.54% -4.79% -9.82% -9.30% -32.87% -28.81% -1.92% 5.01% 13.08% 4.31%
Tax Burden Percent		 98.29% 111.71% 100.00% 101.51% 99.48% 92.85% 97.69% 77.90% 89.95% 148.50%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.10% 10.05% -48.50%
Return on Invested Capital (ROIC)		 -2.78% -1.54% -3.05% 0.00% -9.74% -10.56% -1.40% 2.78% 4.51% 2.69%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1.58% -1.51% -2.63% 0.00% -5.68% -8.79% -2.11% 0.91% 2.65% 3.14%
Return on Net Nonoperating Assets (RNNOA)		 0.24% 0.24% 0.42% 0.00% 0.98% 1.61% 0.38% -0.18% -0.56% -0.69%
Return on Equity (ROE)		 -2.54% -1.29% -2.63% 0.00% -8.75% -8.95% -1.02% 2.59% 3.95% 2.00%
Cash Return on Invested Capital (CROIC)		 3.06% -0.88% 0.56% 0.00% -0.91% 1.41% -8.54% -210.44% -8.11% -6.63%
Operating Return on Assets (OROA)		 -2.88% -1.08% -2.62% 0.00% -10.07% -9.87% -0.63% 2.08% 5.15% 1.07%
Return on Assets (ROA)		 -2.83% -1.21% -2.62% 0.00% -10.02% -9.16% -0.61% 1.62% 4.64% 1.59%
Return on Common Equity (ROCE)		 -2.54% -1.29% -2.63% 0.00% -8.75% -8.95% -1.02% 2.59% 3.95% 2.00%
Return on Equity Simple (ROE_SIMPLE)		 -4.13% 0.00% -2.79% 0.00% -4.74% 0.00% -6.09% -4.77% -0.79% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.78 -3.79 -7.35 -5.64 -22 -25 -3.26 3.59 11 6.20
NOPAT Margin		 -8.96% -4.73% -8.92% -6.24% -24.66% -25.31% -3.37% 3.14% 9.33% 5.23%
Net Nonoperating Expense Percent (NNEP)		 -1.20% -0.03% -0.43% 0.00% -4.06% -1.77% 0.71% 1.87% 1.86% -0.44%
Return On Investment Capital (ROIC_SIMPLE)		 - -0.35% - - - -2.37% - - - 0.52%
Cost of Revenue to Revenue		 34.41% 57.42% 31.82% 38.20% 35.98% 38.92% 32.49% 31.91% 31.81% 36.07%
SG&A Expenses to Revenue		 23.28% 18.54% 25.54% 27.73% 18.13% 24.23% 27.06% 27.74% 22.22% 22.69%
R&D to Revenue		 14.25% 14.06% 15.49% 13.88% 14.78% 19.02% 16.49% 14.39% 15.17% 16.26%
Operating Expenses to Revenue		 78.40% 73.34% 80.91% 76.04% 104.58% 106.24% 72.32% 66.61% 60.34% 65.24%
Earnings before Interest and Taxes (EBIT)		 -8.88 -3.44 -8.09 -8.28 -30 -30 -1.91 7.36 17 3.44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.55 3.12 -1.42 -1.42 -22 -24 3.68 13 23 9.70
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.13 1.58 1.49 0.00 1.54 1.92 1.49 1.46 2.22 2.61
Price to Tangible Book Value (P/TBV)		 6.10 8.33 7.34 0.00 6.85 7.96 6.70 6.18 8.57 9.36
Price to Revenue (P/Rev)		 4.19 5.74 5.17 5.61 4.73 5.57 4.43 4.15 6.15 6.88
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 127.14
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.79%
Enterprise Value to Invested Capital (EV/IC)		 1.16 1.70 1.59 0.00 1.67 2.16 1.60 1.58 2.59 3.10
Enterprise Value to Revenue (EV/Rev)		 3.62 5.16 4.57 0.00 4.15 4.97 3.89 3.57 5.52 6.27
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 152.76 56.84
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 108.63
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 184.77
Enterprise Value to Operating Cash Flow (EV/OCF)		 164.37 203.04 99.84 0.00 37.09 40.60 39.04 28.37 35.51 37.24
Enterprise Value to Free Cash Flow (EV/FCFF)		 36.60 0.00 277.01 0.00 0.00 147.49 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.15 -0.16 -0.16 0.00 -0.17 -0.18 -0.18 -0.20 -0.21 -0.22
Leverage Ratio		 1.07 1.08 1.08 0.00 1.07 1.07 1.07 1.09 1.08 1.09
Compound Leverage Factor		 1.07 1.08 1.08 0.00 1.07 1.07 1.07 1.09 1.08 1.09
Debt to Total Capital		 0.67% 0.56% 0.31% 0.00% 0.24% 0.25% 0.62% 0.64% 0.62% 1.42%
Short-Term Debt to Total Capital		 0.67% 0.56% 0.31% 0.00% 0.24% 0.25% 0.62% 0.64% 0.62% 1.42%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.33% 99.44% 99.69% 0.00% 99.76% 99.75% 99.38% 99.36% 99.38% 98.58%
Debt to EBITDA		 -0.32 -0.58 -0.84 0.00 -0.12 -0.05 -0.16 -0.25 0.48 0.35
Net Debt to EBITDA		 7.34 16.46 46.81 0.00 9.02 4.33 4.56 7.67 -17.35 -5.54
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.21 -0.21 -0.13 0.00 -0.07 -0.04 -0.12 -0.16 -0.45 1.12
Net Debt to NOPAT		 4.85 6.01 7.38 0.00 5.13 3.56 3.61 4.85 16.18 -18.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 9.10 12.54 12.27 0.00 13.65 16.91 12.25 9.82 16.00 14.99
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 4.09 3.97 4.46 0.00 4.74 4.66 5.00 4.44 5.08 4.73
Quick Ratio		 3.60 3.56 4.02 0.00 4.22 4.19 4.41 3.96 4.59 4.27
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 55 17 23 901 8.90 47 -25 -899 -44 -66
Operating Cash Flow to CapEx		 409.92% 520.51% -218.73% 454.37% 505.75% 622.83% -420.15% 1,067.69% 1,336.44% 592.22%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.25 0.25 0.27 0.00 0.30 0.32 0.32 0.32 0.35 0.37
Accounts Receivable Turnover		 7.06 6.94 7.34 0.00 8.65 8.56 8.43 7.94 9.66 10.26
Inventory Turnover		 8.27 9.47 8.70 0.00 8.08 8.64 7.90 6.24 6.87 7.79
Fixed Asset Turnover		 0.00 18.08 17.88 0.00 18.79 18.86 18.74 17.93 21.01 20.48
Accounts Payable Turnover		 8.75 9.96 8.61 0.00 10.15 10.57 9.43 9.94 11.22 13.68
Days Sales Outstanding (DSO)		 51.73 52.61 49.76 0.00 42.21 42.66 43.27 45.95 37.80 35.58
Days Inventory Outstanding (DIO)		 44.16 38.54 41.98 0.00 45.15 42.26 46.19 58.50 53.11 46.83
Days Payable Outstanding (DPO)		 41.71 36.65 42.37 0.00 35.97 34.53 38.69 36.71 32.52 26.68
Cash Conversion Cycle (CCC)		 54.17 54.49 49.37 0.00 51.40 50.40 50.77 67.74 58.39 55.73
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 884 902 894 0.00 853 829 915 903 908 902
Invested Capital Turnover		 0.31 0.33 0.34 0.00 0.39 0.42 0.42 0.89 0.48 0.51
Increase / (Decrease) in Invested Capital		 -62 -21 -31 -907 -31 -72 21 903 55 73
Enterprise Value (EV)		 1,025 1,530 1,421 0.00 1,425 1,796 1,461 1,428 2,348 2,797
Market Capitalization		 1,188 1,703 1,609 1,844 1,625 2,009 1,664 1,657 2,615 3,069
Book Value per Share		 $14.64 $14.98 $15.01 $0.00 $14.49 $14.30 $14.90 $14.81 $15.31 $15.17
Tangible Book Value per Share		 $2.72 $2.85 $3.04 $0.00 $3.26 $3.46 $3.31 $3.50 $3.97 $4.23
Total Capital		 1,055 1,081 1,086 0.00 1,057 1,047 1,126 1,140 1,183 1,193
Total Debt		 7.10 6.06 3.36 0.00 2.57 2.66 6.93 7.35 7.39 17
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -163 -173 -188 0.00 -200 -214 -202 -229 -267 -272
Capital Expenditures (CapEx)		 1.71 1.87 0.99 3.67 2.80 2.50 2.13 2.77 2.24 4.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 17 13 14 0.00 14 11 30 20 20 21
Debt-free Net Working Capital (DFNWC)		 187 192 205 0.00 216 227 239 256 294 311
Net Working Capital (NWC)		 180 186 201 0.00 214 224 232 249 287 294
Net Nonoperating Expense (NNE)		 1.95 0.05 0.74 2.77 7.40 3.44 -1.40 -2.15 -4.35 1.09
Net Nonoperating Obligations (NNO)		 -164 -174 -189 0.00 -201 -215 -203 -230 -268 -274
Total Depreciation and Amortization (D&A)		 6.32 6.56 6.67 6.86 7.32 6.34 5.59 5.74 5.88 6.25
Debt-free, Cash-free Net Working Capital to Revenue		 6.05% 4.46% 4.35% 0.00% 4.08% 2.93% 8.02% 5.06% 4.67% 4.75%
Debt-free Net Working Capital to Revenue		 66.04% 64.78% 65.78% 0.00% 63.09% 62.88% 63.73% 64.10% 69.11% 69.68%
Net Working Capital to Revenue		 63.53% 62.73% 64.70% 0.00% 62.34% 62.15% 61.89% 62.26% 67.37% 65.87%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.12) ($0.06) $0.00 $0.00 ($0.41) ($0.38) ($0.02) $0.07 $0.20 $0.07
Adjusted Weighted Average Basic Shares Outstanding		 71.66M 71.55M 0.00 0.00 72.80M 72.64M 74.76M 76.54M 77.01M 76.48M
Adjusted Diluted Earnings per Share		 ($0.12) ($0.06) $0.00 $0.00 ($0.41) ($0.38) ($0.02) $0.07 $0.19 $0.07
Adjusted Weighted Average Diluted Shares Outstanding		 71.66M 71.55M 0.00 0.00 72.80M 72.64M 74.76M 77.16M 78.46M 78.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 71.75M 72.15M 0.00 0.00 73.04M 75.07M 76.45M 76.81M 77.50M 77.94M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.78 -3.79 -6.36 -5.64 2.21 -2.43 -2.96 3.59 11 4.85
Normalized NOPAT Margin		 -8.96% -4.73% -7.72% -6.24% 2.46% -2.47% -3.06% 3.14% 9.47% 4.09%
Pre Tax Income Margin		 -11.74% -4.29% -9.82% -9.16% -33.04% -31.03% -1.97% 6.43% 14.54% 2.90%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Veracyte's Financials

When does Veracyte's financial year end?

According to the most recent income statement we have on file, Veracyte's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Veracyte's net income changed over the last 9 years?

Over the last 9 years, Veracyte's net income changed from -$33.70 million in 2015 to $24.14 million in 2024, a change of -171.6%.

What is Veracyte's operating income?
Veracyte's total operating income in 2024 was $16.14 million, based on the following breakdown:
  • Total Gross Profit: $298.15 million
  • Total Operating Expenses: $293.56 million
How has Veracyte revenue changed over the last 9 years?

Over the last 9 years, Veracyte's total revenue changed from $49.50 million in 2015 to $445.76 million in 2024, a change of 800.5%.

How much debt does Veracyte have?

Veracyte's total liabilities were at $124.07 million at the end of 2024, a 75.2% increase from 2023, and a 417.1% increase since 2015.

How much cash does Veracyte have?

In the past 9 years, Veracyte's cash and equivalents has ranged from $33.89 million in 2017 to $349.36 million in 2020, and is currently $239.09 million as of their latest financial filing in 2024.

How has Veracyte's book value per share changed over the last 9 years?

Over the last 9 years, Veracyte's book value per share changed from 1.85 in 2015 to 15.17 in 2024, a change of 719.1%.


Related Companies

This page (NASDAQ:VCYT) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
James Altucher: Do not invest in AI unless…
I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...
Paradigm Press | Sponsored
The Exact July Date the AI Correction Will End?
AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...
Brownstone Research | Sponsored
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...
Colonial Metals | Sponsored
Trump’s treachery
Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...
Porter & Company | Sponsored
Two Unmistakable Patterns Return…
The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...
Golden Portfolio | Sponsored